|
Match
|
Document |
Document Title |
|
|
7217795 |
Tumor suppressor designated TS10q23.3
A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene...
|
|
|
7217794 |
Compounds and methods for treatment of thrombosis
The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention...
|
|
|
7217796 |
Neutralizing human anti-IGFR antibody
The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing...
|
|
|
7211559 |
Factor VIII compositions and methods
The present invention provides methods of increasing the half-life and/or specific activity of factor VIII. More specifically, the invention provides methods of increasing the half-life and/or...
|
|
|
7211644 |
Diagnostic markers of human female infertility
Methods and reagents for the diagnosis of female infertility, prognostic indicators for female infertility, compounds for the treatment of female infertility, compounds and methods for...
|
|
|
7211651 |
Proteinaceous gels having visualization agents and methods of use thereof
Proteinaceous gels having visualization agents and methods of use thereof are disclosed herein. Further, polymeric crosslinking agents are disclosed that have an inert water soluble polymeric...
|
|
|
7202346 |
Antibodies to non-shed Muc1 and Muc16, and uses thereof
The present invention relates to antibodies, antibody fragments, conjugates of antibodies and antibody fragments with cytotoxic agents, and hybridomas producing the antibodies and antibody...
|
|
|
7183108 |
Selection and uses of lactic acid bacteria strains modulating non-specific immunity
The invention concerns lactic acid bacteria strains capable of regulating the production of NO and inflammatory cytokines by enterocytes, depending on the inflammatory condition of said...
|
|
|
7179887 |
Guinea pig proteinase-activated receptor 4 and its activating peptide
This invention relates to nucleic acid encoding guinea pig PAR 4 and to the protein encoded thereby. The guinea pig DNA and protein are useful for the development of models of human platelet...
|
|
|
7172999 |
Method and preparations for stabilizing biological materials by drying methods without freezing
The present invention concerns processes for the production of dry, partially amorphous products containing biologically active and in particular therapeutically active material which are...
|
|
|
7169898 |
Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular...
|
|
|
7157556 |
Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
Disclosed are deglycosylated fragments of a kringle 1-3 region of plasminogen, nucleotides encoding deglycosylated kringle 1-3 region proteins and antibodies specific for deglycosylated kringle 1-3...
|
|
|
7153830 |
Method for inhibiting the formation of seromas using factor XIII
Use of factor XIII for inhibiting the formation of seromas by administering factor XIII. The factor XIII can be administered locally at the site of a wound or surgery or administered systemically....
|
|
|
7132508 |
Mammalian chemokine reagents
A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. A chemokine receptor is also...
|
|
|
7129329 |
Heme proteins hemAT-Hs and hemAT-Bs and their use in medicine and microsensors
The present invention provides an isolated archael and bacterial heme binding protein which reversibly binds oxygen with a low affinity. The heme binding protein may be utilized as a blood...
|
|
|
7125841 |
Mutant human factor IX with an increased resistance to inhibition by heparin
The present invention is related to a novel composition of matter and methods of using the same. More particularly, the invention describes mutant human factor IX which has an increased resistance...
|
|
|
7122634 |
Modified factor VIII
Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor...
|
|
|
7119170 |
Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
Methods and compositions are provided for the diagnosis and treatment of iron overload diseases and iron deficiency diseases.
|
|
|
7119069 |
Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
Human kininogen domain 3 (HK-D3) polypeptides and biologically active variants and derivatives of HK-D3 are anti-angiogenic. These molecules are used to inhibit angiogenesis or treat a disease or...
|
|
|
7118924 |
Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents
An improved method for producing human antibodies in SCID mice is provided. The improvement includes the use of dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes...
|
|
|
7115262 |
Chimeric protein for prevention and treatment of HIV infection
This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an...
|
|
|
7115583 |
Microbubble compositions and methods for oligonucleotide delivery
The invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic agents. The methods and composition of the invention can be used with several...
|
|
|
RE39321 |
Supplemented and unsupplemented tissue sealants, methods of their production and use
This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds,...
|
|
|
7078490 |
Artificial antibody polypeptides
A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding a monobody, and a variegated nucleic acid library encoding a monobody, are provided by the invention. Also...
|
|
|
7074892 |
Thrombin generation inhibitors
Peptides derived from amino acids 307 to 356 of the human blood coagulation factor Va are provided. Such peptides comprise: i) a length of between 3 and 50 amino acids, ii) a minimum of 3...
|
|
|
7067268 |
Antibodies and utilization thereof
The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2...
|
|
|
7057019 |
Crosslinked albumin hydrogels
Materials, methods, and compositions for making crosslinked albumin hydrogels are included in the application. Embodiments include a biocompatible material of albumin crosslinked with an...
|
|
|
7045601 |
Storage-stable, liquid fibrinogen formulation
The present invention relates to a novel storage-stable formulation for fibrinogen in liquid or viscous liquid form comprising divalent metal ions. The fibrinogen formulation may comprise other...
|
|
|
7041635 |
Factor VIII polypeptide
The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about...
|
|
|
7041790 |
Fibrinogen binding moieties
Compositions comprising non-naturally occurring fibrinogen binding moieties are described, together with methods of use thereof, e.g., for detecting or isolating fibrinogen molecules in a solution,...
|
|
|
7033994 |
Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
The present invention provides a pharmaceutical composition for treatment and prevention of bleeding disorders caused by platelet disorders, not caused by defect in blood coagulation factors or von...
|
|
|
7015194 |
Pharmaceutical composition comprising factor VIIa and anti-TFPI
The present invention relates to the use of factor VIIa and TFPI inhibitor in the treatment or prophylaxis of bleeding episodes or coagulative treatment.
|
|
|
7015198 |
Materials for soft tissue augmentation and methods of making and using same
Materials for soft tissue augmentation in mammals are prepared by cross-linking blood plasma proteins, preferably with a zero-length cross-linking agent. The cross-linked blood plasma proteins can...
|
|
|
7015193 |
Compositions and methods to control bleeding
Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for...
|
|
|
7008800 |
Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers...
|
|
|
7001993 |
Human antithrombin variants
Human antithrombin variants showing a high protease inhibitory activity even in the absence of heparin wherein at least one of the amino acids at positions 78, 278, 378 and 380 in the amino acid...
|
|
|
7001989 |
Conjugates comprising two active agents
The present invention pertains to a pharmaceutical conjugate comprising an insoluble carrier to which first and second active agents are bound, respectively via a first linker to a first functional...
|
|
|
7001715 |
Purification of red blood cells by separation and diafiltration
Red blood cells are purified by separating whole blood, such as by centrifugation, to form a red blood cell fraction and a liquid fraction. The whole blood can be defibrinated or treated to prevent...
|
|
|
6986984 |
Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier
Red blood cells are purified by defibrinating whole blood and then filtering the defibrinated whole blood, whereby at least a portion of a plasma component is separated from the red blood cells to...
|
|
|
6967108 |
Human monoclonal antibodies to the islet cell antigen IA-2
The invention concerns human monoclonal antibodies to the islet cell antigen IA-2, a process for their production, the use of human monoclonal antibodies in a method for detecting antibodies to...
|
|
|
6960352 |
Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent
The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or...
|
|
|
6956105 |
Chandra: a Th1-specific protein
The present invention provides nucleic acid and protein sequences for a novel Th-1 cell-specific protein, Chandra. The herein-disclosed sequences can be used for any of a number of purposes,...
|
|
|
6953674 |
Inhibitors of human plasmin derived from the kunitz domains
The invention features novel polypeptides homologous to the first Kunitz domain (K1) of lipoprotein associated coagulation inhibitor (LACI) that are capable of inhibiting plasmin, and nucleic acids...
|
|
|
6936423 |
Anti-LTNF for in vitro assay of biological toxins
Lethal Toxin Neutralizing Factor has been isolated in purity from opossum serum by high pressure liquid chromatography (HPLC) fractionation. The amino acid sequence from the N-terminal for the...
|
|
|
6930087 |
Pharmaceutical composition comprising factor VIII and neutral liposomes
A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and substantially neutral colloidal particles. The particles...
|
|
|
6924267 |
Methods and active substances for protecting organs
The present invention comprises a method of protecting organs or tissue susceptible to reperfusion-induced dysfunction after ischemia. The method comprises parenterally administering to a patient a...
|
|
|
6924151 |
Stable factor VIII/vWF-complex
There are disclosed a stable factor VIII/vWF-complex, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation...
|
|
|
6921808 |
Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc-globulin and a Gc-globulin medicinal product
A purification process for large-scale production of Gc-globulin is described. The source of Gc-globulin is preferably a crude plasma fraction but can be any solution, suspension or supernatant...
|
|
|
6916911 |
Use of fibrinogen multimers
Use of fibrinogen multimers having at least 6 fibrinogen units as an ingredient for a fibrin sealant.
|
|
|
6911316 |
Medical uses of scuPA/suPAR complex
Methods of using a complex (scuPA/suPAR) which has thrombolytic activity under physiological conditions and in the presence of IgG, or of at least one IgG-derived peptide, which complex comprises a...
|